SCHEMBL10144693

SCHEMBL10144693

CC(C)(Oc1ccc(Cl)cc1)c1nc(-c2ccncc2)no1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 9/20 0.54
NPC1 O15118 8/20 0.54
LMNA P02545 5/20 0.54
SMN1; SMN2 Q16637 6/20 0.47
HPGD P15428 3/20 0.46
KMT2A Q03164 2/20 0.46
MEN1 O00255 1/20 0.46
DUSP3 P51452 1/20 0.45
PTPN11 Q06124 1/20 0.45
MAPT P10636 3/20 0.44
TSHR P16473 3/20 0.44
HTT P42858 2/20 0.44
TP53 P04637 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
S1PR1 P21453 3/20 0.43
S1PR3 Q99500 2/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
KDM4E B2RXH2 1/20 0.42
NFKB1 P19838 1/20 0.42
CASP3 P42574 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13271394 0.75 NPC1 (0.61) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL23917850 0.74 NR1H4 (0.56) RAB9ANPC1SMN1; SMN2KMT2ATSHR
SCHEMBL5959908 0.70 RAB9A (0.72) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL5959904 0.70 RAB9A (1.00) RAB9ANPC1LMNASMN1; SMN2HPGD
SCHEMBL22322456 0.69 HDAC6 (0.63) RAB9ANPC1S1PR1S1PR3
SCHEMBL17377373 0.69 NOTUM (0.53) RAB9ANPC1SMN1; SMN2KMT2AMAPT
SCHEMBL18105078 0.68 HDAC4 (0.51)
SCHEMBL18105080 0.67 HDAC4 (0.53) CASP3
SCHEMBL25914360 0.67 TSHR (0.55) RAB9ANPC1LMNASMN1; SMN2TSHR
SCHEMBL25914437 0.67 TSHR (0.52) RAB9ANPC1LMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS BIOMARIN PHARMACEUTICAL INC. 2012-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120100609-A1 N-LINKED GLYCAN BIOSYNTHESIS MODULATORS ENGASE, GALNT1, GALNT13 RAB9A 3256/4885NPC1 764/4885LMNA 4109/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.